Active Ingredient History

NOW
  • Now
Ceftobiprole (Zevtera/Mabelio) is a fifth-generation cephalosporin for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica in the United Kingdom, Germany, Switzerland and Austria under the trade name Zevtera, in France and Italy under the trade name Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis.   Wikipedia

  • SMILES: CC1=C(COC(=O)N2CC[C@H](C2)N3CC\C(=C/C4=C(N5[C@H](SC4)[C@H](NC(=O)\C(=N\O)\c6nsc(N)n6)C5=O)C(=O)O)\C3=O)OC(=O)O1
  • InChIKey: HFTSMHTWUFCYMJ-FDNJTQOMSA-N
  • Mol. Mass: 690.67
  • ALogP: -0.54
  • ChEMBL Molecules:
More Chemistry
bal5788 | bal 5788 | bal-5788 | bal5788-001 | bal9141 | bal 9141 | bal-9141 | bal 9141-000 | bal9141-000 | ceftobiprole | ceftobiprole medocaril | ceftobiprole medocaril free acid | ceftobiprole medocaril (inn) | ceftobiprole medocaril sodium | ro-639141 | ro 65-5788 | ro-655788 | zeftera | zevtera

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue